Brief: Sinomab Bioscience Says Investigational NDA For Atopic Dermatitis Accepted By Center For Drug Evaluation Of NMPA
12/06/2023 12:33
June 12 (Reuters) - SinoMab BioScience Ltd 3681.HK :
* SINOMAB BIOSCIENCE - ON 9 JUNE INVESTIGATIONAL NEW DRUG
APPLICATION FOR ATOPIC DERMATITIS FOR SM17 ACCEPTED BY CENTER
FOR DRUG EVALUATION OF NMPA
* SINOMAB BIOSCIENCE LTD - PLANS TO INITIATE A PHASE I
CLINICAL
STUDY IN CHINA UPON APPROVAL OF PRESENT IND
Further company coverage: 3681.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sinomab Bioscience
See all newsBrief: Sinomab Bioscience Posts HY Loss Of RMB127.4 Million
Brief: Sinomab Bioscience Says Fang Liang Resigns As Executive Director
Brief: Sinomab Bioscience Announces Major Deal For Disposal Of Suzhou Property And Facility For RMB280 MLN
Brief: SinoMab Bioscience Appoints Fang Liang As Executive Director
Brief: Hainan Haiyao Plans To Unload Stake In Sinomab Bioscience